Overview

Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective: Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax.
Phase:
Phase 1
Details
Lead Sponsor:
Samyang Biopharmaceuticals Corporation
Treatments:
Docetaxel